Since oral administration of acetylcysteine may result in vomiting or aggravate vomiting associated with paracetamol overdosage, patients at risk of gastric hemorrhage should be evaluated with regard to the relative risks of upper GI hemorrhage and paracetamol-induced hepatotoxicity and treatment with acetylcysteine given accordingly.
Asthmatic patients receiving acetylcysteine should be observed closely during such therapy; if bronchospasm occurs, a bronchodilator should be given by nebulization. If bronchospasm progresses, acetylcysteine should be discontinued immediately.
An increased volume of liquefied bronchial secretions may develop after administration of acetylcysteine. If cough is inadequate to maintain an open airway during acetylcysteine therapy, mechanical suction or endotracheal aspiration should be instituted.
Stacytine contains aspartame. Aspartame is a source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly. Stacytine contains sorbitol. Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product.
Stacytine can be used in pregnant and nursing women.
Caution should be exercised when driving or operating machinery because acetylcysteine can cause some adverse reactions such as drowsiness, headache, blurred vision.